MCID: ACT113
MIFTS: 46

Acute Myeloblastic Leukemia with Maturation

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Acute Myeloblastic Leukemia with Maturation

MalaCards integrated aliases for Acute Myeloblastic Leukemia with Maturation:

Name: Acute Myeloblastic Leukemia with Maturation 20 58 6 17
Acute Myeloblastic Leukemia M2 20 58
Aml M2 20 58
Acute Myeloblastic Leukemia Type 2 20
Acute Myeloid Leukemia 70
Lam M2 20

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C92.0
UMLS via Orphanet 71 C1879321
Orphanet 58 ORPHA98834
UMLS 70 C1879321

Summaries for Acute Myeloblastic Leukemia with Maturation

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 98834 Definition A rare, acute myeloid leukemia characterized by evidence of granulocytic maturation and more than 20% of blast cells in the bone marrow and/or peripheral blood. The maturing non-blast granulocytic cells account for greater than or equal to 10% and monocytic cells less than or equal to 20% of the bone marrow cells. Various degrees of anemia, thrombocytopenia, or pancytopenia are present. Frequent clinical manifestations include fatigue, fever, bleeding disorders, and organomegaly, especially hepatosplenomegaly.

MalaCards based summary : Acute Myeloblastic Leukemia with Maturation, also known as acute myeloblastic leukemia m2, is related to leukemia, acute myeloid and leukemia. An important gene associated with Acute Myeloblastic Leukemia with Maturation is MIR181A1HG (MIR181A1 Host Gene), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Nicotine and Amsacrine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 73 Acute myeloblastic leukemia with maturation (M2) is a subtype of acute myeloid leukemia... more...

Related Diseases for Acute Myeloblastic Leukemia with Maturation

Diseases related to Acute Myeloblastic Leukemia with Maturation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 29.5 NPM1 KIT FLT3
2 leukemia 29.5 NPM1 KIT FLT3
3 myeloid leukemia 29.5 NPM1 KIT FLT3
4 mastocytosis 29.5 KIT FLT3
5 myelodysplastic syndrome 29.4 NPM1 KIT FLT3
6 thrombocytopenia 29.2 NPM1 KIT FLT3
7 hematologic cancer 29.1 NPM1 KIT FLT3
8 hypereosinophilic syndrome 10.3
9 chromosomal triplication 10.2
10 leukemia, chronic myeloid 10.1
11 pancytopenia 10.1
12 exophthalmos 10.1
13 tetraploidy 10.1
14 pelger-huet anomaly 10.1
15 acute monoblastic leukemia 10.1
16 posttransplant acute limbic encephalitis 10.1
17 acute monoblastic/monocytic leukemia 10.1
18 acute myeloblastic leukemia without maturation 10.0 NPM1 FLT3
19 cytogenetically normal acute myeloid leukemia 9.9 NPM1 FLT3
20 hypertriglyceridemia, familial 9.9
21 leukemia, acute monocytic 9.9
22 polykaryocytosis inducer 9.9
23 lymphoma, hodgkin, classic 9.9
24 lymphoma, non-hodgkin, familial 9.9
25 aspergillosis 9.9
26 invasive aspergillosis 9.9
27 follicular lymphoma 9.9
28 neutropenia 9.9
29 monocytic leukemia 9.9
30 bacterial pneumonia 9.9
31 monosomy 21 9.9
32 complex chromosomal rearrangement 9.9
33 partial duplication of chromosome 4 9.9
34 refractory anemia 9.9
35 mesenchymal cell neoplasm 9.8 NPM1 KIT
36 acute myeloid leukemia with t(8;21)(q22;q22) translocation 9.8 KIT FLT3
37 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8 KIT FLT3
38 core binding factor acute myeloid leukemia 9.8 KIT FLT3
39 8p11 myeloproliferative syndrome 9.8 KIT FLT3
40 myelodysplastic/myeloproliferative neoplasm 9.7 KIT FLT3
41 myeloproliferative neoplasm 9.7 KIT FLT3
42 chronic eosinophilic leukemia 9.7 KIT FLT3
43 inflammatory myofibroblastic tumor 9.7 NPM1 KIT
44 mast cell neoplasm 9.7 KIT FLT3
45 aggressive systemic mastocytosis 9.7 KIT FLT3
46 chronic leukemia 9.7 KIT FLT3
47 leukocyte disease 9.6 KIT FLT3
48 b-lymphoblastic leukemia/lymphoma 9.6 KIT FLT3
49 blood platelet disease 9.6 KIT FLT3
50 blood coagulation disease 9.5 KIT FLT3

Graphical network of the top 20 diseases related to Acute Myeloblastic Leukemia with Maturation:



Diseases related to Acute Myeloblastic Leukemia with Maturation

Symptoms & Phenotypes for Acute Myeloblastic Leukemia with Maturation

GenomeRNAi Phenotypes related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.46 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.46 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.46 FLT3 KIT
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.44 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.44 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.44 KIT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.44 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.44 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.44 FLT3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.44 FLT3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.44 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.44 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.44 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.44 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.44 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.44 KIT
17 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.65 FLT3

MGI Mouse Phenotypes related to Acute Myeloblastic Leukemia with Maturation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.8 FLT3 KIT NPM1

Drugs & Therapeutics for Acute Myeloblastic Leukemia with Maturation

Drugs for Acute Myeloblastic Leukemia with Maturation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Amsacrine Approved, Investigational Phase 4 51264-14-3 2179
3
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
4
Lenalidomide Approved Phase 4 191732-72-6 216326
5 Interferon-alpha Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Angiogenesis Inhibitors Phase 4
8
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
9
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
10
Atorvastatin Approved Phase 3 134523-00-5 60823
11
Lactitol Approved, Investigational Phase 3 585-86-4 157355
12
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
13
Enalaprilat Approved Phase 3 76420-72-9 6917719
14
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
15
Isavuconazole Approved, Investigational Phase 2, Phase 3 241479-67-4
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
18
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
19
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
20
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
21
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
22
Iodine Approved, Investigational Phase 3 7553-56-2 807
23
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
25
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
26
Mercaptopurine Approved Phase 3 50-44-2 667490
27
Morphine Approved, Investigational Phase 3 57-27-2 5288826
28
Nalbuphine Approved Phase 3 20594-83-6 5311304 5360630
29
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
30
Abatacept Approved Phase 3 332348-12-6 10237
31
Captopril Approved Phase 3 62571-86-2 44093
32
midostaurin Approved, Investigational Phase 3 120685-11-2 9829523 104937
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
34
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
35
Idarubicin Approved Phase 3 58957-92-9 42890
36
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
37
Etoposide Approved Phase 3 33419-42-0 36462
38
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
39
Hydroxyurea Approved Phase 3 127-07-1 3657
40
Coal tar Approved Phase 2, Phase 3 8007-45-2
41
Thioguanine Approved Phase 3 154-42-7 2723601
42
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
43
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 2, Phase 3 14838-15-4 26934
44
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
45
Lenograstim Approved, Investigational Phase 3 135968-09-1
46
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
47
Melphalan Approved Phase 3 148-82-3 4053 460612
48
Mycophenolic acid Approved Phase 3 24280-93-1 446541
49
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704 32326
50
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 1583)
# Name Status NCT ID Phase Drugs
1 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
2 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
3 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
5 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
7 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
8 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Unknown status NCT02926586 Phase 4 Fludarabine;Cytarabine
9 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
10 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
11 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
12 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
13 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
14 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
15 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
16 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
17 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
18 Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy Recruiting NCT04484532 Phase 4
19 A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
20 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
21 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
22 PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5 Terminated NCT01198054 Phase 4 Lenalidomide
23 Randomised Prospective Comparison of the nonmyélo-Ablative Allograft and the Traditional Allograft in Acute Myeloid Leukaemia in Complete Remission of the Adult Unknown status NCT00224614 Phase 3
24 The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients Unknown status NCT01633099 Phase 3 Decitabine
25 A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old Unknown status NCT03257241 Phase 3 A arm (DA-90);B arm (DAC);A arm (CLAG-M);B arm (FLAG-IDA)
26 Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable Unknown status NCT02473146 Phase 2, Phase 3 Gemtuzumab ozogamicin (GO)
27 A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
28 Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors Unknown status NCT03066466 Phase 3 Atorvastatin;Methotrexate;Tacrolimus
29 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
30 Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2 Unknown status NCT03887156 Phase 2, Phase 3
31 Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia Unknown status NCT02985372 Phase 3 Decitabine;Cytarabine
32 Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
33 Phase III Clinical Trial of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
34 Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
35 Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells Unknown status NCT02072811 Phase 3 DAC;CLAG;Consolidation, I HAM cycle;II Consolidation HiDAraC;Consolidation, III HiDAraC cycle
36 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
37 Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2 Unknown status NCT00149162 Phase 3 proleukin
38 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
39 A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia Unknown status NCT01145846 Phase 3 Cytarabine plus Daunorubicin [Arm II (AD regimen)]
40 Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in Acute Myeloid Leukemia (AML) Unknown status NCT03701217 Phase 2, Phase 3 Eltrombopag
41 Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
42 A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation Completed NCT00049517 Phase 3 busulfan;cyclophosphamide;cytarabine;gemtuzumab ozogamicin (GO);Daunorubicin
43 A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
44 A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens Completed NCT00317642 Phase 3 clofarabine (IV formulation);placebo;cytarabine
45 Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies Completed NCT01110824 Phase 3 Enalapril and carvedilol
46 Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission. Completed NCT01191957 Phase 3 Busulphan plus Cyclophosphamide;Busulphan plus Fludarabine
47 A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR) Completed NCT01191801 Phase 3 vosaroxin + cytarabine;placebo + cytarabine
48 Randomized Phase 3 Trial of Decitabine Versus Patient's Choice With Physician's Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00260832 Phase 3 Cytarabine or Supportive Care;Dacogen (decitabine) only
49 A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) &gt; / = 60 Years Completed NCT00085124 Phase 3 cytarabine;daunorubicin hydrochloride
50 Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia Completed NCT00480064 Phase 3 Lomustine, intermediate dose cytarabine

Search NIH Clinical Center for Acute Myeloblastic Leukemia with Maturation

Genetic Tests for Acute Myeloblastic Leukemia with Maturation

Anatomical Context for Acute Myeloblastic Leukemia with Maturation

MalaCards organs/tissues related to Acute Myeloblastic Leukemia with Maturation:

40
Myeloid, T Cells, Bone Marrow, Bone, Nk Cells, Endothelial, Eye

Publications for Acute Myeloblastic Leukemia with Maturation

Articles related to Acute Myeloblastic Leukemia with Maturation:

(show top 50) (show all 476)
# Title Authors PMID Year
1
Lentivirus-mediated RNA interference targeting FAMLF-1 inhibits cell growth and enhances cell differentiation of acute myeloid leukemia partially differentiated cells via inhibition of AKT and c-MYC. 6
29254171 2017
2
Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia. 61
33739029 2021
3
Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. 61
33488804 2021
4
OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. 61
33748146 2021
5
Long non-coding RNA HOTAIR regulates myeloid differentiation through the upregulation of p21 via miR-17-5p in acute myeloid leukaemia. 61
33241756 2020
6
Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients. 61
32056080 2020
7
Down syndrome presenting with different hematological manifestations: A case series of four cases. 61
32754549 2020
8
[Acute myeloid leukemia with inversion of chromosome 16: cytological, immunophenotypic and cytogenetic disruption]. 61
32319947 2020
9
Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center. 61
31725954 2020
10
Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia. 61
32362604 2020
11
Unbalanced Whole-Arm Translocation der(18;21)(q10;q10) in Hematological Malignancies. 61
32889803 2020
12
Vulvar myeloid sarcoma as the presenting symptom of acute myeloid leukemia: a case report and literature review of Chinese patients, 1999-2018. 61
31699112 2019
13
Unusual Karyotype in Acute Myelomonocitic Leukemia: A Case Report. 61
31366525 2019
14
New perspectives on treatment strategies for patient with acute myeloid leukemia and complex karyotype abnormalities after percutaneous coronary intervention: A case report. 61
31348297 2019
15
Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement. 61
30848074 2019
16
[Donor HSCs with a preexisting ASXL1-mutation evoluting FLT3-ITD positive AML-M2 and FLT3-ITD negative AML-M5 in the donor and recipient respectively: one case analysis and literatures review]. 61
31104446 2019
17
Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report. 61
30921216 2019
18
The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter. 61
30637949 2019
19
Isolated myeloid sarcoma of the temporal bone: As the first clinical manifestation of acute myeloid leukemia in a patient of down's syndrome. 61
31015077 2019
20
Expression Analysis of PVT1, CCDC26, and CCAT1 Long Noncoding RNAs in Acute Myeloid Leukemia Patients. 61
30222365 2018
21
Polymorphisms of the CYR61 gene in patients with acute myeloid leukemia in a Han Chinese population. 61
30142822 2018
22
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. 61
29286103 2018
23
[Clinical Study of Patients with Myelodysplastic Syndrome Transformed into Acute Myeloid Leukemia]. 61
29397844 2018
24
Acute myeloid leukemia presenting as erythema nodosum: A case report. 61
29381943 2017
25
Trisomy 21 with t(5; 11) chromosomal translocation as new unfavorable cytogenetic abnormalities in pediatric acute myeloid leukemia type M2: One case report of nine-year follow-up and literature review. 61
29058300 2017
26
[Distribution of Type 9 T Helper Cells and Expression of Transcriptional Factors in Acute Myeloid Leukemia]. 61
29070098 2017
27
LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. 61
28765931 2017
28
Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype. 61
28194056 2017
29
Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia. 61
28406995 2017
30
MYC Amplification in the Form of Ring Chromosomes 8 in Acute Myeloid Leukemia with t(11;16)(q13;p11.2). 61
29393095 2017
31
[Expression of WT1 gene in children with acute myeloid leukemia]. 61
27974109 2016
32
[Correlations Between AML1-ETO Fusion Gene and Clinical Features of Acute Myeloid Leukemia in Sichuan.] 61
28598127 2016
33
Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. 61
27863755 2016
34
Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)/CD34(+) aptamer. 61
27514505 2016
35
De Novo Philadelphia Positive Acute Myeloid Leukemia with Extensive Basophilia: A Diagnostic Dilemma. 61
27408364 2016
36
Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics. 61
26526573 2016
37
[The study of 4 cases of myeloid neoplasm with t (5;12) (q33;p13) and the literatures review]. 61
27093993 2016
38
Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study. 61
27382304 2016
39
Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran. 61
27054117 2016
40
Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo Acute Myeloid Leukemia with t(11;20)(p15;q12) and t(2;5)(q33;q31). 61
28249294 2016
41
Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience. 61
25843763 2015
42
The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia. 61
27352183 2015
43
Treatment-related myelodysplastic syndrome in a child with acute myeloid leukemia and TPMT heterozygosity. 61
25000470 2015
44
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome]. 61
25948187 2015
45
Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature. 61
25960852 2015
46
In vivo and in vitro effects of heme oxygenase-1 silencing on the survival of acute myelocytic leukemia-M2 cells. 61
25667656 2015
47
[Subcutaneous myeloid sarcoma in a patient with essential thrombocythemia that transformed into acute myeloid leukemia]. 61
25743142 2015
48
[Prognostic impact of loss of sex chromosomes in children with acute myeloid leukemia subtype M2]. 61
25760843 2015
49
Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors. 61
24897507 2015
50
Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. 61
25760770 2015

Variations for Acute Myeloblastic Leukemia with Maturation

ClinVar genetic disease variations for Acute Myeloblastic Leukemia with Maturation:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MIR181A1HG NR_040073.1(MIR181A1HG):n.363+1456C>T SNV Pathogenic 427755 rs10800597 GRCh37: 1:198868084-198868084
GRCh38: 1:198898955-198898955
2 MIR181A1HG NR_040073.1(MIR181A1HG):n.364-18748G>A SNV Pathogenic 427753 rs12406470 GRCh37: 1:198796120-198796120
GRCh38: 1:198826991-198826991
3 MIR181A1HG NR_040073.1(MIR181A1HG):n.363+26A>G SNV Pathogenic 427756 rs10800598 GRCh37: 1:198869514-198869514
GRCh38: 1:198900385-198900385
4 MIR181A1HG NR_040073.1(MIR181A1HG):n.363+1862C>A SNV Pathogenic 427754 rs60639710 GRCh37: 1:198867678-198867678
GRCh38: 1:198898549-198898549

Expression for Acute Myeloblastic Leukemia with Maturation

Search GEO for disease gene expression data for Acute Myeloblastic Leukemia with Maturation.

Pathways for Acute Myeloblastic Leukemia with Maturation

GO Terms for Acute Myeloblastic Leukemia with Maturation

Biological processes related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.52 KIT FLT3
2 peptidyl-tyrosine phosphorylation GO:0018108 9.51 KIT FLT3
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.49 KIT FLT3
4 positive regulation of MAPK cascade GO:0043410 9.48 KIT FLT3
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 KIT FLT3
6 B cell differentiation GO:0030183 9.43 KIT FLT3
7 positive regulation of cell proliferation GO:0008284 9.43 NPM1 KIT FLT3
8 positive regulation of kinase activity GO:0033674 9.4 KIT FLT3
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.37 KIT FLT3
10 hemopoiesis GO:0030097 9.32 KIT FLT3
11 positive regulation of MAP kinase activity GO:0043406 9.16 KIT FLT3
12 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 8.96 KIT FLT3
13 myeloid progenitor cell differentiation GO:0002318 8.62 KIT FLT3

Molecular functions related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.96 KIT FLT3
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.62 KIT FLT3

Sources for Acute Myeloblastic Leukemia with Maturation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....